

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7574046

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
APTUIT (VERONA) SRL, AN EVOTEC COMPANY	11/19/2020
RECEIVING PARTY DATA	
Name:	AMGEN INC.
Street Address:	ONE AMGEN CENTER DRIVE
City:	THOUSAND OAKS
State/Country:	CALIFORNIA
Postal Code:	91320-1799
PROPERTY NUMBERS Total: 6	
Property Type	Number
Application Number:	62939819
Application Number:	17103350
Application Number:	62939821
Application Number:	17103389
PCT Number:	US2062011
PCT Number:	US2062020
CORRESPONDENCE DATA	
Fax Number:	(805)499-8011
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	617.444.5563
Email:	aparke01@amgen.com
Correspondent Name:	AMGEN INC,
Address Line 1:	ONE AMGEN CENTER DRIVE
Address Line 4:	THOUSAND OAKS, CALIFORNIA 91320-1799
ATTORNEY DOCKET NUMBER:	A-2233/A-2445
NAME OF SUBMITTER:	ALLISON E. PARKER
SIGNATURE:	/Allison E. Parker/
DATE SIGNED:	10/04/2022
Total Attachments: 3	

source=Aptuit-Amgen#page1.tif

source=Aptuit-Amgen#page2.tif

source=Aptuit-Amgen#page3.tif

PATENT

REEL: 061309 FRAME: 0399

ASSIGNMENT

WHEREAS APTUIT (VERONA) SRL, AN EVOTEC COMPANY, a corporation having its registered office at Via Alessandro Fleming, 4, 37135 Verona, Italy, (hereinafter referred to as "ASSIGNOR"), is the owner and in any event the assignee of its entire right, title and interest in Patent Applications listed in the attached Schedule A ("Application"); and

Whereas AMGEN INC., a corporation organized under the laws of the State of Delaware and having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA wishes to acquire the entire right, title, and interest in all inventions disclosed in such Application;

Now, therefore, for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR hereby sells, assigns, transfers and sets over unto AMGEN INC., its successors and assigns (collectively "ASSIGNEE") ASSIGNOR'S entire right, title and interest in, to and under the Application, and any provisional application(s) from which Application is derived, and all priority rights to which the Application may be entitled, including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all Letters Patent of the United States and of all other countries which may be granted for such inventions, or any of them, including divisional, continuation, continuation-in-part, substitute, reissue, and/or reexamination applications based on the above identified Application, all such inventions and all rights in such Application and Letters Patent to be held and enjoyed by ASSIGNEE for its own use and enjoyment to the full end of the term or terms for which such Letters Patent may be granted, and any extensions thereof, as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had this assignment and sale not been made.

ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States and any foreign Patent Office authority to issue any such Letters Patent which may be granted on the Application to ASSIGNEE as assignee of the entire right, title and interest therein and thereto.

For ASSIGNOR and for ASSIGNOR'S legal representatives, ASSIGNOR covenants and agrees with ASSIGNEE that ASSIGNOR has not granted to any others any license to make, use or sell any of such inventions, that ASSIGNOR'S right, title and interest in such inventions has not been encumbered, that ASSIGNOR has good right and title to sell and assign the same, and that ASSIGNOR will not execute any instrument in conflict herewith.

For ASSIGNOR and for ASSIGNOR'S successors and legal representatives, ASSIGNOR further covenants and agrees with ASSIGNEE that upon request ASSIGNOR and ASSIGNOR'S successors and legal representatives will: (i) communicate to ASSIGNEE any facts known to ASSIGNOR or ASSIGNOR'S successors and legal representatives relating to such inventions or the history thereof; (ii) execute and deliver any application papers, assignments, or other instruments; and (iii) do all other acts which, in the opinion of counsel for ASSIGNEE, may be necessary or desirable to secure the grant of Letters Patent to ASSIGNEE or its nominees, in the United States and in all other countries where ASSIGNEE may desire to have such inventions, or any of them, patented, with specifications and claims in such form as shall be approved by counsel

for ASSIGNEE and to vest and confirm in ASSIGNEE or its nominees the full and complete legal and equitable title to all such Letters Patent, without further consideration than that now paid at the expense of ASSIGNEE.

APTUIT (VERONA) SRL, AN EVOTEC COMPANY

By: 

Name: Ciriaco Maraschiello

Title: EVP & Global Head of Drug Development
Site Head, Verona

Date: 19/11/2020

By: 

Name: Elisabetta Verardo

Title: EVP Head of Global Drug Development
Quality Unit

Date: 19/11/2020

DECLARATION OF ACCEPTANCE

On behalf of Assignee,


Stuart L. Watt
Name

Vice President, Law and Intellectual Property Officer
Title

hereby confirms Assignee's acceptance.

November 19, 2020


Date


Signature

SCHEDULE A

Application Type	Serial No.	Filing Date	Title	Amgen Ref. No.
US Provisional	62/939,819	November 25, 2019	HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE	A-2233-US-PSP
International Application	<u>PCT/US20/62011</u>	<u>November 24, 2020</u>	HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE	A-2233-US-NP
US Application	<u>17/103,350</u>	<u>November 24, 2020</u>	HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE	A-2233-WO-PCT
US Provisional	62/939,821	November 25, 2019	HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE	A-2445-US-PSP
International Application	<u>PCT/US20/62020</u>	<u>November 24, 2020</u>	HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE	A-2445-US-NP
US Application	<u>17/103,389</u>	<u>November 24, 2020</u>	HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE	A-2445-WO-PCT

ASSIGNOR hereby authorizes and requests ASSIGNEE or its legal representative to insert herein above the application number and filing date of said Application when known.

 6-Sept-22